DENALI THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Description as filed by funds: Election of Directors: Jay Flatley

DENALI THERAPEUTICS INC.’s own tally for this item (“Elect Director: Jay Flatley”): 108,094,205 for, 2,149,100 withheld, per its Form 8-K filed May 31, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Each of the following nominees was elected to serve as a Class I director, to hold office until the Company's 2027 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified or his or her earlier resignation or removal.”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 66 asset managers below reported 44,758,381 for, 1,141,996 withheld, 18,833 abstained.

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

Description as filed by funds: ELECTION OF DIRECTORS: Marc Tessier-Lavigne, Ph.D.

DENALI THERAPEUTICS INC.’s own tally for this item (“Elect Director: Mac Tessier-Lavigne, Ph.D.”): 82,215,374 for, 28,027,931 withheld, per its Form 8-K filed May 31, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Each of the following nominees was elected to serve as a Class I director, to hold office until the Company's 2027 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified or his or her earlier resignation or removal.”
Support: 75% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 66 asset managers below reported 36,552,123 for, 9,192,671 withheld, 174,416 abstained.

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

Description as filed by funds: ELECTION OF DIRECTORS: Nancy Thornberry

DENALI THERAPEUTICS INC.’s own tally for this item (“Elect Director: Nancy A. Thornberry”): 108,270,582 for, 1,972,723 withheld, per its Form 8-K filed May 31, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Each of the following nominees was elected to serve as a Class I director, to hold office until the Company's 2027 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified or his or her earlier resignation or removal.”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 66 asset managers below reported 44,758,381 for, 1,141,996 withheld, 18,833 abstained.

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

Description as filed by funds: Advisory Vote to Ratify Named Executive Officers' Compensation

DENALI THERAPEUTICS INC.’s own tally for this item (“3. Advisory Vote to Approve Executive Compensation”): 101,612,037 for, 8,587,858 against — passed, per its Form 8-K filed May 31, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3 - Advisory Vote to Approve Executive Compensation The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 67 managers: 42,248,744 for, 3,951,916 against, 19,493 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 196 managers: 61,483,021 for, 7,733,596 against, 95 abstained, 4,200 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2024

DENALI THERAPEUTICS INC.’s own tally for this item (“2. Ratification of Appointment of Independent Registered Public Accounting Firm The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, ”): 117,978,800 for, 297,039 against — passed, per its Form 8-K filed May 31, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2 - Ratification of Appointment of Independent Registered Public Accounting Firm The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 was ratified based on the following results of voting:”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 67 asset managers below reported 45,875,590 for, 24,192 against, 19,493 abstained.

Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.